Dennis Wolf Biography and Net Worth

Director of Codexis

As a retired CFO of DataStax, Inc. and previously as executive vice president and CFO of Fusion-io Multisystems and MySQL AB, Dennis Wolf brings significant experience in financial management, corporate finance and public company corporate governance to Codexis. Wolf also held financial management positions for public high-technology companies including Apple Computer, Centigram Communications, Credence Systems Corporation, Omnicell, Redback Networks and Sun Microsystems. He has been a director and chair of the audit committee for other public companies including Quantum Corporation, Avanex Corporation, Bigband Networks, Komag, Inc., Registry Magic, Vitria Technology and Exponential Interactive. He earned a bachelor’s degree from the University of Colorado and an MBA from the University of Denver.

What is Dennis P. Wolf's net worth?: The estimated net worth of Dennis P. Wolf is at least $242,811.36 as of March 25th, 2021. Mr. Wolf owns 45,987 shares of Codexis stock worth more than $242,811 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Wolf may own. Learn More about Dennis P. Wolf's net worth.
How do I contact Dennis P. Wolf?: The corporate mailing address for Mr. Wolf and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Dennis P. Wolf's contact information.
Has Dennis P. Wolf been buying or selling shares of Codexis?: Dennis P. Wolf has not been actively trading shares of Codexis during the last quarter. Most recently, Dennis P. Wolf sold 4,000 shares of the business's stock in a transaction on Wednesday, March 23rd. The shares were sold at an average price of $20.49, for a transaction totalling $81,960.00. Learn More on Dennis P. Wolf's trading history.
Who are Codexis' active insiders?: Codexis' insider roster includes Byron Dorgan (Director), Bernard Kelley (Director), John Nicols (CEO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.
Are insiders buying or selling shares of Codexis?: In the last year, Codexis insiders bought shares 4 times. They purchased a total of 1,166,000 shares worth more than $3,514,910.00. The most recent insider tranaction occured on September, 25th when Major Shareholder Opaleye Management Inc. bought 5,000 shares worth more than $14,300.00. Insiders at Codexis own 2.1% of the company. Learn More about insider trades at Codexis.
Information on this page was last updated on 9/25/2024.

Dennis P. Wolf Insider Trading History at Codexis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/23/2022	Sell	4,000	$20.49	$81,960.00
12/20/2021	Sell	5,000	$28.83	$144,150.00
10/15/2021	Sell	6,000	$28.30	$169,800.00
3/25/2021	Sell	10,000	$20.44	$204,400.00	45,987
12/21/2020	Sell	10,000	$19.99	$199,900.00	51,129
9/24/2020	Sell	10,000	$11.68	$116,800.00	61,129
6/25/2020	Sell	10,000	$10.97	$109,700.00	71,129
3/25/2020	Sell	10,000	$10.38	$103,800.00	72,777
12/19/2019	Sell	20,000	$16.22	$324,400.00	102,177
2/26/2019	Sell	9,000	$21.96	$197,640.00
12/26/2018	Sell	9,000	$15.83	$142,470.00	86,230
8/20/2018	Sell	18,333	$15.24	$279,394.92	120,896
6/12/2018	Sell	8,947	$14.41	$128,926.27	122,177
3/27/2018	Sell	41,666	$11.15	$464,575.90	157,920
8/29/2016	Sell	18,000	$4.22	$75,960.00	132,360
6/15/2015	Sell	35,416	$4.10	$145,205.60

Dennis P. Wolf Buying and Selling Activity at Codexis

Codexis Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Today's Range

Now: $5.28

$5.07

$5.48

50 Day Range

MA: $4.22

$2.91

$5.81

2 Week Range

Now: $5.28

$2.53

$6.08

Volume

3,250,119 shs

Average Volume

569,688 shs

Market Capitalization

$429.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.